glp 1 agonist prediabetes GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Glucagon-like peptide-1 (GLP-1) receptor agonists

The latest research and trials on the effect of GLP-1RAs in the eye were searched until April 2025, including thorough cellular studies, animal studies, and clinical observation surrounding glaucoma, diabetic retinopathy, and other ocular diseases

Between 1969 and 1971, work by John Brown and Raymond Pederson, together with the peptide chemistry expertise of Erik Jorpes and Viktor Mutt [67], led to the identification of the gastric inhibitory polypeptide (GIP), a 42-amino acid polypeptide that was named based on its potency to suppress gastric motility and gastric acid secretion [[68], [69], [70]]

Chan School of Public Health in Boston, and colleagues estimated the risk for nonlive birth, abnormal fetal growth, and MCM with GLP-1 RA dispensing in early pregnancy in an observational cohort of pregnant women aged 16 to 55 years with a GLP-1 RA dispensation in the 90 days before the last menstrual period (LMP)

At their worst, side effects such as vomiting and nausea or hypoglycemia can land you in the emergency room

Mounjaro is approved only for type 2 diabetes

The Bottom Line on GLP-1 Safety Research consistently shows that GLP-1 medications are safe for most people when used appropriately under medical supervision